Med Intensiva (Engl Ed). 2021 Jun 10; doi: 10.1016/j.medin.2021.04.010. Epub 2021 Jun 10.
Effects of sodium bicarbonate infusion on mortality in medical-surgical ICU patients with metabolic acidosis-A single-center propensity score matched analysis.
Medicina intensiva
[Article in Spanish]
J Waskowski, B Hess, L Cioccari, I Irincheeva, C A Pfortmueller, J C Schefold
Affiliations
Affiliations
- Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: [email protected].
- Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Center of Intensive Care Medicine, Luzerner Kantonsspital, Lucerne, Switzerland.
- Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- CTU Bern, University of Bern, Switzerland.
PMID: 34120787
DOI: 10.1016/j.medin.2021.04.010
Abstract
OBJECTIVE: Metabolic acidosis is associated with high mortality. Despite theoretical benefits of sodium-bicarbonate (SB), current evidence remains controversial. We investigated SB-related effects on outcomes in ICU patients with metabolic acidosis.
DESIGN: Retrospective analysis.
SETTING: Academic medical center.
PATIENTS OR PARTICIPANTS: 971 ICU patients with metabolic acidosis defined as arterial pH<7.3 and CO
INTERVENTIONS: 441 patients were treated with SB 8.4% (SB-group) and n=530 patients were not (control group).
MAIN VARIABLES OF INTEREST: Primary outcome was all-cause mortality at ICU-discharge. Average Treatment Effect (ATE), Average Treatment effect in Treated (ATT), and estimated relative survival effects at 20 days were computed.
RESULTS: In the full cohort, we observed considerable differences in pH, base excess, additional acidosis-related indices, and ICU mortality (controls 31% vs. SB-group 56%, p<.001) at baseline between the two groups. After PS-matching (n=174 in each group), no significant difference in ICU mortality was observed (controls 32% vs. SB-group 41%; p=.07). Odds ratios (OR) for ATE and ATT showed no association with ICU mortality (OR ATE: 1.08, 95%-CI 0.99-1.17; p=.08; OR ATT 1.09; 95%-CI 0.99-1.2; p=.09). Hazard ratios at 20-days (multivariable HR, matched sample n=348: 1.16, 95%-CI 0.86-1.56, p=.33) showed similar survival in the two study groups.
CONCLUSIONS: We did not observe effects of SB infusion on all-cause mortality in critically ill patients with metabolic acidosis.
Copyright © 2021 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.
Keywords: Acidosis metabólica; Bicarbonato de sodio; Critical illness; Enfermedad crítica; ICU; Metabolic acidosis; Mortalidad; Mortality; Sodium bicarbonate; UCI
Publication Types